Description: Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Home Page: www.scancell.co.uk
SCLP Technical Analysis
Bellhouse Building
Oxford,
OX4 4GD
United Kingdom
Phone:
44 18 6558 2066
Officers
| Name | Title |
|---|---|
| Prof. Lindy Gillian Durrant Ph.D. | Founder, CEO, Chief Scientific Officer & Director |
| Dr. Sally Elizabeth Adams | Chief Devel. Officer & Director |
| Mr. Keith Green | Director of Fin. & Admin. and Company Sec. |
| Dr. Samantha Paston Ph.D. | Head of Translational Research |
| Dr. Adrian Parry Ph.D. | Head of Manufacturing |
| Ms. Akua Asare | Head of Quality |
| Mr. Fayaz Master | Head of Clinical Operations |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.9289 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 40 |